The ACC launched its latest registry knowing that volumes at these outpatient facilities are expected to rise in the years ahead. 

The panel's decision will be based on data from the TRILUMINATE study, which was ultimately positive for Abbott, but did lead to certain questions about patient outcomes.

The rise of TAVR as a go-to treatment option for many AS patients has been one of the biggest stories in cardiology for several years now. How will advanced AI models impact this trend going forward? 

Hospital end users ranked the CVIS and hemodynamic systems they use, shedding light on their working relationships with IT vendors. 

The VIRTUE and POLARIS studies are both focused on evaluating how the Varipulse PFA Platform performs in a variety of clinical scenarios. 

TAVR continues to gain momentum as a go-to treatment option for severe AS, making it more important than ever to investigate long-term outcomes. This latest analysis, published in European Heart Journal, focused on 280 patients randomized to undergo either transcatheter or surgical aortic valve replacement.

One of the world's leading heart hospitals is seeing significant growth. This represents the first time it has hired four new cardiothoracic surgeons in a single 12-month period. 

Researchers explored the potential of an alternate way to perform PFA on patients with persistent AFib, presenting their findings live at AF Symposium 2024 in Boston.